Adakveo Avrupa Birliği - Hırvatça - EMA (European Medicines Agency)

adakveo

novartis europharm limited - crizanlizumab - anemija, sickle cell - other hematological agents - adakveo is indicated for the prevention of recurrent vaso occlusive crises (vocs) in sickle cell disease patients aged 16 years and older. it can be given as an add on therapy to hydroxyurea/hydroxycarbamide (hu/hc) or as monotherapy in patients for whom hu/hc is inappropriate or inadequate.

Oxbryta Avrupa Birliği - Hırvatça - EMA (European Medicines Agency)

oxbryta

pfizer europe ma eeig  - voxelotor - anemia; anemia, hemolytic; anemia, sickle cell - other hematological agents - oxbryta is indicated for the treatment of haemolytic anaemia due to sickle cell disease (scd) in adults and paediatric patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide.

TOT’HEMA 50mg/10ml + 1.33mg/10ml + 0.7mg/10ml Oralni rastvor Karadağ - Hırvatça - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

tot’hema 50mg/10ml + 1.33mg/10ml + 0.7mg/10ml oralni rastvor

"evropa lek pharma" doo podgorica - gvožđe (ii) glukonat, hidrat, mangan glukonat, bakar glukonat - oralni rastvor - 50mg/10ml + 1.33mg/10ml + 0.7mg/10ml

POLYGYNAX 100.000i.j. + 35.000i.j. + 35.000i.j. Vaginalna kapsula, meka Karadağ - Hırvatça - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

polygynax 100.000i.j. + 35.000i.j. + 35.000i.j. vaginalna kapsula, meka

"evropa lek pharma" doo podgorica - nistatin, neomicin, polimiksin b - vaginalna kapsula, meka - 100.000i.j. + 35.000i.j. + 35.000i.j.

POLYGYNAX 100.000i.j. + 35.000i.j. + 35.000i.j. Vaginalna kapsula, meka Karadağ - Hırvatça - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

polygynax 100.000i.j. + 35.000i.j. + 35.000i.j. vaginalna kapsula, meka

"evropa lek pharma" doo podgorica - nistatin, neomicin, polimiksin b - vaginalna kapsula, meka - 100.000i.j. + 35.000i.j. + 35.000i.j.

Zydelig Avrupa Birliği - Hırvatça - EMA (European Medicines Agency)

zydelig

gilead sciences ireland uc - idelalisib - lymphoma, non-hodgkin; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, other antineoplastic agents - zydelig is indicated in combination with an anti‑cd20 monoclonal antibody (rituximab or ofatumumab) for the treatment of adult patients with chronic lymphocytic leukaemia (cll):who have received at least one prior therapy, oras first line treatment in the presence of 17p deletion or tp53 mutation in patients who are not eligible for any other therapies. zydelig is indicated as monotherapy for the treatment of adult patients with follicular lymphoma (fl) that is refractory to two prior lines of treatment.

Teysuno Avrupa Birliği - Hırvatça - EMA (European Medicines Agency)

teysuno

nordic group b.v. - тегафур, gimeracil, oteracil - neoplazme želuca - antineoplastična sredstva - teysuno is indicated in adults:- for the treatment of advanced gastric cancer when given in combination with cisplatin (see section 5. - as monotherapy or in combination with oxaliplatin or irinotecan, with or without bevacizumab, for the treatment of patients with metastatic colorectal cancer for whom it is not possible to continue treatment with another fluoropyrimidine due to hand-foot syndrome or cardiovascular toxicity that developed in the adjuvant or metastatic setting.

TOT`HEMA 50 mg/10 mL+ 1.33 mg/10 mL+ 0.7 mg/10 mL oralni rastvor Bosna Hersek - Hırvatça - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

tot`hema 50 mg/10 ml+ 1.33 mg/10 ml+ 0.7 mg/10 ml oralni rastvor

phoenix d.o.o. bijeljina, donja ljeljenča 015b, ljeljenča, bijeljina - bakarglukonat, gvožđe, manganglukonat - oralni rastvor - 50 mg/10 ml+ 1.33 mg/10 ml+ 0.7 mg/10 ml - 10 ml oralnog rastvora sadrži: 50 mg gvožđe (u obliku gvožđe (ii)glukonata) 1,33 mg mangan (u obliku mangan (ii)glukonata) 0,70 mg bakar (u obliku bakarglukonata)